Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin:: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells

被引:95
作者
Jiang, C [1 ]
Agarwal, R [1 ]
Lü, JX [1 ]
机构
[1] AMC Canc Res Ctr, Ctr Canc Causat & Prevent, Denver, CO 80214 USA
关键词
silymarin; HUVEC; MMP-2/gelatinase A; in vitro capillary differentiation; vascular endothelial growth factor; angiogenesis switch;
D O I
10.1006/bbrc.2000.3474
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In recent studies, we have shown that silymarin, a naturally occurring flavonoid antioxidant, exhibits anti-cancer effects against several epithelial cancers. Here, we assessed its potential as an anti-angiogenic agent employing human umbilical vein endothelial cells (HUVEC) and human prostate and breast cancer epithelial cells. When sub-con fluent HUVEC were treated for 48 h, adherent cell number decreased by 50 and 90% at 50 and 100 mu g/ml doses, respectively. Apoptotic cell death principally accounted for cell loss at >50 mu g/ml doses. In biochemical analysis, silymarin treatment of HUVEC for 6 h resulted in a concentration-dependent decrease in the secretion and cellular content of matrix metalloproteinase (MMP)-2/gelatinase A. Silymarin also inhibited HUVEC tube formation tin vitro capillary differentiation) on a reconstituted extracellular matrix, Matrigel. In other studies, 5 to 6 h exposure of DU145 prostate, and MCF-7 and MDA-MB-468 breast cancer cells to silymarin resulted in a dose-dependent decrease in the secreted vascular endothelial growth factor (VEGF) level in conditioned media without any visible change in cell morphology. The inhibitory effect of silymarin on VEGF secretion occurred as early as 1 h. These observations indicate a rapid inhibitory action of silymarin on the secretion of this primary angiogenic cytokine by cancer epithelial cells. Taken together, the results of this study support the hypothesis that silymarin possesses an anti-angiogenic potential that may critically contribute to its cancer chemopreventive efficacy, (C) 2000 Academic Press.
引用
收藏
页码:371 / 378
页数:8
相关论文
共 55 条
[1]  
AbuJawdeh GM, 1996, LAB INVEST, V74, P1105
[2]   INHIBITORY EFFECT OF SILYMARIN, AN ANTIHEPATOTOXIC FLAVONOID, ORE 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED EPIDERMAL ORNITHINE DECARBOXYLASE ACTIVITY AND MESSENGER-RNA IN SENCAR MICE [J].
AGARWAL, R ;
KATIYAR, SK ;
LUNDGREN, DW ;
MUKHTAR, H .
CARCINOGENESIS, 1994, 15 (06) :1099-1103
[3]   Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression [J].
Ahmad, N ;
Gali, H ;
Javed, S ;
Agarwal, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (02) :294-301
[4]   Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways [J].
Arbiser, JL ;
Moses, MA ;
Fernandez, CA ;
Ghiso, N ;
Cao, YH ;
Klauber, N ;
Frank, D ;
Brownlee, M ;
Flynn, E ;
Parangi, S ;
Byers, HR ;
Folkman, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :861-866
[5]   Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal [J].
Benjamin, LE ;
Keshet, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8761-8766
[6]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[7]  
Borgström P, 1998, PROSTATE, V35, P1
[8]  
Borgstrom P, 1996, CANCER RES, V56, P4032
[9]  
Brown JM, 1998, CANCER RES, V58, P1408
[10]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].
BROWN, LF ;
BERSE, B ;
JACKMAN, RW ;
TOGNAZZI, K ;
GUIDI, AJ ;
DVORAK, HF ;
SENGER, DR ;
CONNOLLY, JL ;
SCHNITT, SJ .
HUMAN PATHOLOGY, 1995, 26 (01) :86-91